Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma

J Clin Oncol. 2011 Oct 1;29(28):e739-42. doi: 10.1200/JCO.2011.36.1865. Epub 2011 Sep 6.

Authors

Emil Lou¹, Scott Turner, Ashley Sumrall, David A Reardon, Annick Desjardins, Katherine B Peters, John H Sampson, Henry S Friedman, James J Vredenburgh

Affiliation

¹ Duke University Medical Center, Durham, NC, USA.

PMID: 21900098
DOI: 10.1200/JCO.2011.36.1865

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab
Brain Neoplasms / drug therapy*
Dacarbazine / administration & dosage
Dacarbazine / analogs & derivatives
Female
Glioblastoma / drug therapy*
Humans
Middle Aged
Posterior Leukoencephalopathy Syndrome / chemically induced*
Temozolomide

Substances

Antibodies, Monoclonal, Humanized
Bevacizumab
Dacarbazine
Temozolomide